【制药网 行业动态】2025年上半年,医药行业高管变动频繁,涉及董事长、总裁、核心技术人员等多个层级。值得一提的是,仅在近半个月内(7月15日-29日),就已有阿斯利康、罗氏制药、中国医药等大批药企宣布人事变动。阿斯利康中国7月29日,阿斯利康公布2025年上半年业绩,实现总营收280.45亿美元,同比增长11%。在财报公布同期,有市场消息称,去年成立的阿斯利康生物制药业务板块(BBU)又有重大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.